Antimycobacterial Activity, Synergism, and Mechanism of Action Evaluation of Novel Polycyclic Amines against Mycobacterium tuberculosis by Kapp, Erika et al.
Research Article
Antimycobacterial Activity, Synergism, and Mechanism of Action
Evaluation of Novel Polycyclic Amines against
Mycobacterium tuberculosis
Erika Kapp ,1 Jacques Joubert ,1 Samantha L. Sampson ,2 Digby F. Warner ,3
Ronnett Seldon ,4 Audrey Jordaan ,3 Margaretha de Vos ,2 Rajan Sharma ,1
and Sarel F. Malan 1
1School of Pharmacy, Faculty of Natural Sciences, University of the Western Cape, Cape Town, South Africa
2DSI/NRF Centre of Excellence for Biomedical Tuberculosis Research, SAMRC Centre for Tuberculosis Research,
Division of Molecular Biology and Human Genetics, Faculty of Medicine and Health Sciences, University of Stellenbosch,
Cape Town, South Africa
3SAMRC/NHLS/UCT Molecular Mycobacteriology Research Unit,
DSI/NRF Centre of Excellence for Biomedical Tuberculosis Research,
Department of Pathology and Institute of Infectious Disease and Molecular Medicine, Faculty of Health Sciences,
University of Cape Town, Cape Town, South Africa
4H3D Drug Discovery and Development Centre, Department of Chemistry, University of Cape Town, Cape Town, South Africa
Correspondence should be addressed to Erika Kapp; ekapp@uwc.ac.za
Received 11 January 2021; Accepted 24 May 2021; Published 21 June 2021
Academic Editor: Heng Yen Khong
Copyright © 2021 Erika Kapp et al. )is is an open access article distributed under the Creative Commons Attribution License,
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Mycobacterium tuberculosis has developed extensive resistance to numerous antimycobacterial agents used in the treatment of
tuberculosis. Insufficient intracellular accumulation of active moieties allows for selective survival of mycobacteria with drug re-
sistance mutations and accordingly promotes the development of microbial drug resistance. Discovery of compounds with new
mechanisms of action and physicochemical properties that promote intracellular accumulation, or compounds that act syner-
gistically with other antimycobacterial drugs, has the potential to reduce and prevent further drug resistance. To this end, anti-
mycobacterial activity, mechanism of action, and synergism in combination therapy were investigated for a series of polycyclic amine
derivatives. Compound selection was based on the presence of moieties with possible antimycobacterial activity, the inclusion of
bulky lipophilic carriers to promote intracellular accumulation, and previously demonstrated bioactivity that potentially support
inhibition of efflux pump activity.)emost potent antimycobacterial demonstrated aminimum inhibitory concentration (MIC99) of
9.6 μM against Mycobacterium tuberculosis H37Rv. Genotoxicity and inhibition of the cytochrome bc1 respiratory complex were
excluded as mechanisms of action for all compounds. Inhibition of cell wall synthesis was identified as a likely mechanism of action
for the two most active compounds (14 and 15). Compounds 5 and 6 demonstrated synergistic activity with the known Rv1258c
efflux pump substrate, spectinomycin, pointing to possible efflux pump inhibition. For this series, the nature of the side chain, rather
than the type of polycyclic carrier, seems to play a determining role in the antimycobacterial activity and cytotoxicity of the
compounds. Contrariwise, the nature of the polycyclic carrier, particularly the azapentacycloundecane cage, appears to promote
synergistic activity. Results point to the possibility of combining an azapentacycloundecane carrier with a side chain that promotes
antimycobacterial activity to develop dual acting molecules for the treatment of Mycobacterium tuberculosis.
Hindawi
Advances in Pharmacological and Pharmaceutical Sciences
Volume 2021, Article ID 5583342, 8 pages
https://doi.org/10.1155/2021/5583342
1. Introduction
)e progressive development of resistance to various che-
motherapeutic agents used in the management of infectious
diseases presents a serious problem in global public health.
Tuberculosis (TB) has re-emerged as one of the most con-
cerning communicable diseases of our time. )e notoriously
complex structure of the mycobacterial cell wall and the
abundance of efflux pumps (EPs) in Mycobacterium tuber-
culosis limit the intracellular accumulation and anti-
mycobacterial efficacy of numerous antimicrobial classes
successfully utilized against standard bacteria [1–4]. Treatment
and control of the TB epidemic is further complicated by the
development of multidrug-resistant (MDR) and extensively
drug-resistant (XDR) strains. Current TB treatment regimens
thus comprise a combination of antimycobacterial agents
which, as drug resistance develops to the various first-line
agents, not only decrease in efficacy and patient acceptability,
but also increase in required treatment duration and toxicity.
Based on their mechanisms of action (MOAs), available
antimycobacterial drugs can be broadly categorized into three
classes: those which disrupt cell wall integrity (e.g., isoniazid,
ethambutol, ethionamide, and cycloserine, as well as the ex-
perimental 1,2-ethylenediamine, SQ109 [5]); those that limit
the energy available for cellular processes (e.g., pyrazinamide
and bedaquiline [6]); and compounds that inhibit normal
cellular functionality by inhibiting or corrupting biosynthesis
of essential macromolecules, cofactors, and metabolites (e.g.,
the rifamycin, fluoroquinolone, aminoglycoside and oxazoli-
dinone class antibiotics, and para-aminosalicylic acid [7–9]).
Reduced susceptibility to these antimycobacterial agents
commonly results from spontaneous mutations in the genome
of mycobacteria with selective survival fueled by suboptimal
exposure to, or reduced intracellular accumulation of, active
moieties [10, 11]. EPs, in particular, have been shown to play a
role in inadequate accumulation of drugs within the myco-
bacterial cell [12]. Depending on the particular mechanism by
which a drug’s action is overcome, resistancemay be specific to
a particular molecule or, more alarmingly, result in reduced
sensitivity to various drugs that target a particular cellular
process (e.g., cell wall synthesis) or act as substrates for an
overexpressed efflux pump.
Strategies that improve the accumulation of anti-
mycobacterial compoundswithin themycobacterial cell would
likely increase the efficacy of the particular compound, but
would also minimize genetically encoded resistance aided by
subinhibitory chemotherapeutic exposure [13]. Approaches
that may promote intracellular accumulation of chemother-
apeutic agents could include increasing cell wall permeability
[14], facilitation of passive transport of drugs into the cell,
alteration of the chemical structure of molecules to reduce
their predisposition to efflux [15], as well as direct efflux pump
inhibition through the utilization of EP inhibitors [16].
As part of a research project designed to evaluate the
possibility of modulating drug resistance and increase ac-
cumulation of active moieties in M. tuberculosis, a series of
polycyclic cage compounds were selected from the Uni-
versity of the Western Cape School of Pharmacy compound
library to be evaluated for antimycobacterial and efflux
pump inhibitory activity in M. tuberculosis. )e polycyclic
cage derivatives included in this study demonstrate, amongst
others, L-type calcium channel and N-methyl-D-Aspartate
(NMDA) inhibitory properties [17] and feature a lipophilic
scaffold likely to improve the barrier permeability of selected
structures. Subsequent research demonstrated the ability of
polycyclic amine derivatives (particularly compounds 3, 5,
and 11, Figure 1) to modulate antimalarial drug resistance
[18–20]. Criteria for the selection of compounds to include
in this study were therefore the presence of moieties with
possible antimycobacterial activity, and the inclusion of
bulky lipophilic carriers to promote compound accumula-
tion within the mycobacterial cell, as well as biological effects
which may promote resistance reversal activity. )e pos-
session of potential ion channel inhibitory properties, which
may directly or indirectly inhibit efflux pump efficacy
[21, 22], was an important consideration in compound
selection.
Here, we report the antimycobacterial activities of the
series of selected compounds and a preliminary investigation
into possible MOAs of the active molecules. We also describe a
possible modulation of Rv1258c efflux pump activity as in-
dicated by synergistic activity with spectinomycin, a known
substrate for the mycobacterial Rv1258c efflux pump [15].
2. Results and Discussion
)e compounds selected for the study were classified into three
categories based on the nature of the polycyclic cage scaffold.
Figure 1 shows the oxapentacycloundecane class (compounds 1,
2, 4, and 8), the azapentacycloundecane class (compounds 3, 5,
6, and 7), and adamantane class (compounds 9–16). Synthesis
of compounds 1–15 (Figure 1) is described in detail in previous
publications by our group, as indicated in Table 1. Compound
16 was purchased from Sigma-Aldrich®.
2.1. Antimycobacterial Activity. Minimum inhibitory con-
centrations (MIC99) of the compounds (Table 1) were de-
termined in nutrient-rich and nutrient-poor media types by
the broth microdilution method utilizing an M. tuberculosis
H37Rv reporter strain expressing GFP [29–31]. Compounds
3, 5, 7, 11, 14, and 15 showed antimycobacterial activity with
MIC99 values ranging from 9.6 μM to 82.2 µM (Table 1);
these were selected for further analysis to determine the
possible MOA.
Interestingly, during MIC determination, compound 5
showed activity in the GAST-Feminimal medium, comprising
glycerol, alanine, salts, iron, and Tween80, but not in the
standard Middlebrook 7H9 albumin-dextrose-catalase (ADC)
medium. )is difference may point to the binding of the
compound by albumin [22], interference of catalase in the
MOA, or an MOA that has an impact on the ability of the
bacillus to use glycerol as the primary carbon source [32]. In
contrast, the activities of compounds 7 and 14 were much
more pronounced in standard 7H9-ADC, while compounds 3,
11, and 15 showed comparable potencies in both media types.
An interesting observation pertaining to the structures of
the compounds versus the observed antimycobacterial ac-
tivity was the differences in MIC for the structurally similar
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compound 1, an oxapentacycloundecane benzyl amine
derivative, and the azapentacycloundecane benzyl amine
derivative, compound 5. Results point towards anti-
mycobacterial activity being linked to the presence of the
tertiary amine and/or free hydroxyl group within the
polycyclic aza-cage. Compounds 11, 14, and 15 containing
an adamantane moiety showed better activity compared to
oxa- and aza-PCU-based compounds in general. )ese are
also the only 3 compounds containing the 1,3-diamine linker
versus the 1,2-diamine present in compounds 3, 6, and 7.
)is increased activity could, therefore, be due to the
presence of the adamantane or the 1,3-diamine linker.
Comparable activity (Figure 2) seen in compounds 2 (oxa-
PCU) and 10 (adamantane derivative), however, suggest that
the increased activity may be linked to the 1,3-diamine linker
rather than the presence of the adamantane moiety.
2.2. Cytotoxicity Analysis. Cytotoxicity of the compounds
was evaluated using a Chinese hamster ovarian (CHO) cell
line (Table 1). )e marked cytotoxicity differences observed
between compounds 3 and 11 were noteworthy. )e ada-
mantane moiety may contribute to increased cytotoxicity,
but, as can be deduced from the similar IC50 values of
compounds 2 and 10, it appears that this molecular feature
cannot be solely responsible for the increased cytotoxicity
observed for compound 11. )e propane-1,3-diamine
linker, however, seems to contribute to cytotoxicity as
compounds 11, 14, and 15 all demonstrate significantly
higher cytotoxicity, even when compared to most com-
pounds containing the similar ethane-1,2-diamine moiety.
)e 1,3-diamine linker unfortunately also seems to play a
role in antimycobacterial activity as these compounds
demonstrate the lowest overall MIC values.
2.3. Preliminary Mechanism of Action Determination. To










































Figure 1: Structures of evaluated compounds grouped according to the respective lipophilic scaffold.
Table 1: Antimycobacterial activity and cytotoxicity data.
Compound MIC99 IC50 CHO7H9-ADC GAST-Fe
1 [23] >125 >125 >10#
2 [24] >125 >125 >322
3 [19] 82.20 82.8 119.00
4 [23] >125 >125 >254
5 [23] 125 80.9 84.80
6 [23] 125 >125 >254
7 [18] 68.70 >125 9.54
8 [25] >125 >125 Nd
9 [26] >125 >125 >414
10 [26] >125 >125 >349
11 [27] 50.00 42.8 7.40
12 [26] >125 >125 >386
13 [28] >125 >125 >100+
14 [25] 9.60 18.8 8.01
15 [25] 13.90 15.2 8.20
16 >125 >125 >100+
Rifampicin 0.0149 0.0274 Nd
Emetine Nd nd 0.061
TB :MIC99 7H9 (μM) in M. tuberculosis H37Rv:gfp. TB :MIC99 GAST-Fe
(μM) in M. tuberculosis H37Rv:gfp. CHO : Chinese hamster ovarian cell
IC50 (μM) as indication of cytotoxicity [18, 19]. nd: not determined. #highest
concentration measured. +CellTiter-Glo® luminescent cell viability assay
[28].
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bioactivity reporter assays were utilized. To evaluate the
possible impact of the compounds on respiration, com-
parative MIC values were determined for the respective
compounds in wild-type M. tuberculosis H37Rv vs. (i) a
cytochrome bd oxidase deficient mutant (∆cydKO) and (ii) a
∆cydKO/qcrBA317T strain to determine possible QcrB in-
hibition [33, 34]. QcrB inhibitors are expected to exhibit
increased potency (lower MIC) in the ∆cydKO but minimal
activity in the ∆cydKO/qcrBA317T strain which carries an
additional Ala317)r point mutation in QcrB [35]. No
significant shift in MIC was observed for any of the com-
pounds against either of the mutant strains, strongly sug-
gesting that none was likely to target QcrB [34, 36].
Next, a real-time bioluminescence assay [37] was used to
investigate cell wall damage as a potential mechanism of
action. Compounds with inhibitory effects on mycobacterial
arabinogalactan, mycolic acid, and fatty acid synthesis have
been shown to result in the upregulation of the iniBAC
operon [38]. )is operon is, however, not upregulated by
other cell wall stressors, for example, exposure to hydrogen
peroxide, heat, acidic conditions, or antibiotics that do not
directly inhibit cell wall synthesis (e.g., aminoglycosides,
fluoroquinolones, or rifampins) [38]. Compounds 14 and 15
were PiniB-LUX positive and showed early (day 1) and
sustained luminescence signals, similar to the luminescence
profile which was observed previously for ethambutol [37].
Figure 2 provides an example of bioluminescence observed
for late and indirect cell wall damage (compound 11), early
cell wall damage (compound 15), and the positive control
SQ109 (also demonstrating early cell wall damage). Com-
parative background-corrected RLU data are presented as
heat maps, ranging from white (minimum) to orange
(maximum) as a function of themaximumRLU recorded for
luminescence control.
Given the presence of the adamantane and amine linker
functional groups in SQ109 [39], it was decided to use SQ109
as a control compound in the PiniB-LUX assay. SQ109 also
demonstrated early luminescence, but the signal was only
sustained for approximately 5 days [37], whereas in the
current study, a continued signal was observed for com-
pounds 14 and 15 over the course of the 14-day assay.
Compounds 3, 7, and 11 were associated with delayed
production of bioluminescence. )is suggests that the im-
pact on cell wall homeostasis might be delayed or a sec-
ondary effect of a compound with polypharmacologic
activity. )ese data suggest that compounds 14 and 15 di-
rectly target cell wall biosynthesis, although the precise
target is still unknown.
Finally, we investigated whether any of the compounds
were genotoxic using the PrecA-LUX bioluminescence re-
porter [37]. RecA is a key regulator of mycobacterial DNA
damage response and is induced after the exposure to
compounds which are directly genotoxic (i.e., altering or
damaging to the nucleic acid) or which inhibit DNA
metabolism (replication and/or repair). Placing the bacterial
luciferase luxCABE cassette under the transcriptional con-
trol of the recA promoter results in increased biolumines-
cence following promoter induction in response to DNA
damage [37]. None of the compounds evaluated in this study
produced a positive luminescence signal over the full du-
ration of the assay, eliminating DNA damage as potential
MOA.
2.4. Synergism Evaluations. It was originally postulated that
compounds from this series might act as mycobacterial
efflux pump inhibitors (EPIs). As an initial screen to de-
termine possible EPI activity, synergism assays were per-
formed using the known Rv1258c efflux pump substrate,
spectinomycin, as an anchor compound. Spectinomycin is
an aminocyclitol antibiotic with a unique binding site on the
bacterial 30S ribosomal subunit which affords it selective
toxicity and a good side effect profile. Unfortunately, mainly
due to extensive efflux by bacterial efflux pumps (specifically
Rv1258c inM. tuberculosis), spectinomycin lacks significant
antibacterial activity [15, 40, 41]. )e activity of spectino-
mycin is increased substantially under conditions where
efflux pump activity is inhibited [42] making it a useful agent
15.62 31.25 62.5 125.0 7.8 15.62 31.25 62.5 0.08 0.156 0.312 0.625
D1 0 0 0 0 D1 40 25 19 137 D1 2 0 45 76
D2 0 0 1 0 D2 207 746 339 21 D2 0 6 733 651
D3 0 0 0 0 D3 1010 2454 151 0 D3 56 247 1009 1106
D5 13 836 1034 0 D5 504 3470 0 0 D5 64 72 139 1041
D7 0 840 1214 0 D7 0 3705 0 0 D7 0 0 34 79
Compound 11 (µM) Compound 15 (µM) SQ109 (µM)
Figure 2: Observed luminescence data of compounds 11, 15, and SQ109 depicting cell wall damage over 7 days (D1–D7) at various
concentration ranges (μM) spanning the MIC90 (as indicated by the red dotted line).
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to screen for possible efflux pump inhibitory activity using
synergism assays. All compounds apart from compounds 14
and 15, which were excluded due to inherent anti-
mycobacterial activity, were screened for synergism with
spectinomycin using a checkerboard assay. To this end, serial
dilutions of the test compound and spectinomycin were
added to an M. tuberculosis culture in 7H9 media on the y-
and x-axis of a 96-well plate. Bacterial growth was measured,
and data were analyzed as described [43]. Compounds 5 and
6 showed evidence of synergism with spectinomycin, but no
significant changes in MIC were observed with any of the
other compounds. Inhibition of bacterial growth for com-
pounds 1, 5, and 6 in combination with spectinomycin is
shown in Figure 3. )e concentration of spectinomycin as a
fraction of its MIC (i.e., 2 = 2×MIC, 1 =MIC, 0.5 = half MIC
etc.) is given on the x-axis, combined with various fractions
of theMIC of the test compound as indicated by the colors in
the graph legend.)e bacterial inhibition as measured in the
spectinomycin-only wells at various multiples of
spectinomycin MIC is depicted as the dark red (top) legend
on the graph. If spectinomycin is combined with a test
compound with which it synergizes, the percentage bacterial
inhibition remains high despite decreases in spectinomycin
concentration. )us, compound 1 (A) which is provided for
purposes of comparison with structurally similar compound
5 shows no evidence of synergism, but bacterial inhibition at
lower concentrations of spectinomycin when combined with
compounds 5 (B) and 6 (C) point to synergistic activity.
Both compound 5 and 6 are aza-cage derivatives. Again,
the differences between the activity of the structurally similar
compounds 1 and 5 (Figure 1) are notable. Similar to what
was seen with the antimycobacterial activity of these two
compounds, the tertiary nitrogen and free hydroxyl group
on the aza-cage are likely involved in the observed syner-
gistic activity. Compounds 3 and 7, contrariwise, appeared
to increase the MIC of spectinomycin at higher concen-
trations (data not shown). )is observation might point to
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(c)
Figure 3: Percentage inhibition of compound 1 (a), 5 (b), and 6 (c) at various concentration combination points where the concentration of
spectinomycin (as a function of MIC) is indicated on the x-axis combined with multiples of the MIC of the test compound as indicated by
the colors in the legend.
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further investigation to determine the mechanism of this
possible antagonism.
3. Conclusions
In this study, we explored possible antimycobacterial ac-
tivity, mechanism of action, and synergistic activity of a
series of polycyclic amine derivatives. )e compounds were
selected based on the presence of pharmacophoric moieties
with possible antimycobacterial activity, previously de-
scribed resistance reversal activity, as well as for the presence
of structural features and bioactivity that may increase the
accumulation of active moieties and coadministered anti-
mycobacterial drugs within M. tuberculosis. )e most active
compound (15) demonstrated an MIC99 of 9.6 μM against
M. tuberculosis H37Rv and will serve as a lead compound to
improve selective antimycobacterial activity.
Inhibition of the bc1 respiratory complex and DNA
functionality as MOA as well as genotoxicity were excluded
for the series. Cell wall damage, however, was identified as
the likely mechanism of action of a number of compounds.
Particularly, compounds 14 and 15 were shown to cause
early and sustained cell wall damage in a fashion similar to
ethambutol. Compounds 3, 7, and 11 showed delayed cell
wall damage which may indicate cell wall stress as a sec-
ondary effect to interference with other cell systems or a
delayed effect on cell wall integrity.
Compounds 5 and 6 showed evidence of synergistic
activity with spectinomycin and thus possible efflux pump
(specifically Rv1258c) inhibition.
)e azapentacycloundecane cage seems to play a role in
the antimycobacterial activity in nutrient poor media as well
as the ability to synergize with spectinomycin as is evident
from the large variances between the structurally similar
compounds 1 and 5 in the respective assays. )e role of the
aza-cage in antimycobacterial and synergistic activity thus
warrants further exploration. Although compounds from
this series do not display sufficiently selective toxicity in
single-drug in vitro assays, the ability of selected compounds
from this series to act as chemosensitizers, may reduce the
required MIC in combination therapy. Results from this
preliminary study have contributed to our understanding of
the structure activity relationships, possible synergistic ac-
tivity, and toxicity for this series of compounds and will be
used in conjunction with ongoing synergism assays to in-
form lead modification. Additional work exploring structure
activity relationships for antimycobacterial activity (versus
cytotoxicity) and, importantly, investigations pertaining to
possible resistance reversal activity are underway in our
laboratories.
4. Materials and Methodology
4.1. Minimum Inhibitory Concentration Determination.
All assays were performed in a Biosafety Level III certified
facility. Mycobacterium tuberculosis pMSp12:GFP [29, 44]
was grown to an optical density (OD) of 0.6–0.7, and assays
were performed using either GAST-Femedia [45, 46] or 7H9
media supplemented with 10% Albumin Dextrose Catalase
(ADC) [45, 46]. 10mM stock solutions of the test com-
pounds in DMSO were serially diluted 2-fold, and plates
were set up as previously described [47]. Rifampicin at
2xMIC was used as a minimum growth control. Relative
fluorescence was measured and used to calculate the MIC as
previously reported [22, 48].
4.2. Cytotoxicity Analysis. )e reduction of 3-[4,5-dimeth-
ylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) in
the presence of living cells was used to evaluate cell viability
[49]. 20mg/mL stock solutions of the test compounds in
10% DMSOwere serially diluted in a complete medium with
10-fold dilutions to obtain 6 concentrations. Cells were
exposed to the respective test compounds for 44 hours after
which MTTwas added and cells were incubated at 37°C for a
further 4 hours. Plates were analyzed at 540 nm using a
spectrophotometer with wells containing untreated cells and
growth medium only used to determine 100% survival and
0% survival, respectively. Emetine was used as a positive
control, and assays were performed in triplicate. Cell via-
bility was not compromised at the highest concentration of
DMSO to which the cells were exposed (data not shown).
IC50 values were obtained from full dose-response curves,
using a nonlinear dose-response curve fitting analysis via
GraphPad Prism v.4 software.
4.3. Respiratory Reporter Assay. Mycobacterium tuberculosis
H37Rv ΔcydKO and Mycobacterium tuberculosis H37Rv
ΔcydKO/QcrBA317T [34, 35] were utilized as described
above for the determination of the minimum inhibitory
concentration (Section 4.1).
4.4. LUX Assays. A modified bioluminescence (LUX) re-
porter assay was used to investigate cell wall damage and
genotoxicity as possible mechanisms of action [37]. A 10ml
culture of the relevant Mycobacterium tuberculosis H37Rv
strain (PiniB-LUX determining cell wall damage or PrecA-
LUX determining DNA damage) was grown to an optical
density (OD600) of ±0.4. )e strain culture was diluted 1 :10
prior to inoculation of the assay. Two-fold serial dilutions of
the test compounds and the assay control drugs were pre-
pared in flat-bottomed 96-well microtiter plates. )e rele-
vant diluted M. tuberculosis reporter culture was added to
each well to a final volume of 100 μl per well. SQ109 and
levofloxacin were used as a positive and negative control,
respectively, in the PiniB-LUX assay, whereas levofloxacin
and ethambutol were utilized as positive and negative
control, respectively, in the PrecA-LUX assay.
Raw luminescent data (Relative Luminescence Units)
were acquired using a SpecraMax i3x Plate reader (Mo-
lecular Devices Corporation, 1311 Orleans Drive, Sunnyvale,
California 94089). Data were corrected for background
luminescence using Softmax® Pro 6 software (Version 6.5.1,Serial no. 1278552768867612530), Molecular Devices Cor-
poration, 1311 Orleans Drive, Sunnyvale, California 94089.
Data were converted to 2-colour 2-dimensional heat maps
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using Microsoft® Excel® for Mac 2011, Version 14.6.5(160527), latest installed update 14.6.5.
4.5. Synergism Assays. Possible drug interactions of the
various test compounds and spectinomycin were investi-
gated utilizing a slightly modified standard two-dimensional
(2D) checkerboard assay [42]. Serially diluted drugs were
dispensed along the x-axis and y-axis of 96-well microtiter
plates, respectively, at a starting concentration 100 times the
final concentration.)e assays were performed as previously
described [42], and results were reported as a percentage
growth inhibition at various drug concentration
combinations.
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